AMERICAN NATUROPATHIC RESEARCH INSTITUTE
NATUROPATHIC ONCOLOGY RESEARCH INSTITUTE
1250 E. Baseline Rd., Suite 205
Tempe, AZ 85283
JOINT MEETING OF THE
AMERICAN NATUROPATHIC RESEARCH INSTITUTE (ANRI)
NATUROPATHIC ONCOLOGY RESEARCH INSTITUTE (NORI)
INTERNATIONAL NATUROPATHIC CLINICAL RESEARCH INSTITUTE
INSTITUTIONAL REVIEW BOARD (IRB)
February 8, 2019
MINUTES AND MEETING NOTES
In accordance with the requirements of the United States Code of Federal Regulations, Title 21, Chapter 1, Subchapter A, Part 56, the thirty-seventh regular quarterly meeting of the American Naturopathic Research Institute (ANRI) and the Naturopathic Oncology Research Institute (NORI) and the International Naturopathic Clinical Research Institute (INCRI) and the Institutional Review Board (IRB) was called to order at 12:00 p.m., February 8, 2019 at 1250 E. Baseline Rd., Suite 205, meeting in Suite 203, Tempe, AZ 85283.
MEMBERS AND GUESTS
8 physicians and 3 non-physicians were in attendance.
CLARIFICATION OF IRB FROM NOVEMBER 2018 MEETING
In our November 2018 meeting, an IRB was passed. Since then, new questions arose related to an IND application, and requirements made by the FDA. We therefore read the part of the FDA letter that pertained to the IRB, and we discussed how the IRB should approach the matter.
We then talked to 2 physicians by phone, the Principal Investigator, as well as the IND applicant. Both made clarifying statements.
So we then drafted a list of requirements that this IRB would stipulate regarding the use of the product. That letter will be emailed to the two doctors at the first opportunity.
The IRB looks forward to learning of the future reported information regarding future patient treatment with the product named in this IND.
After talking to both of those off-site doctors, the letter was edited by the group, and then a motion was made and seconded to send this letter by email to both physicians. The motion passed unanimously, with no nays.
On a related matter, some of the doctors have not been able to reach one of the doctors or their staff at their office. He has been advised that some of us have been trying to reach him.
One physician described a matter that came up recently with the AZ Naturopathic Physicians Board.
What are ANRI / NORI’s views and wishes regarding how to proceed, if at all?
On the specialist certificate, it has to be granted by an entity approved by the Board. Interest in this topic was expressed by those present in our meeting. We agreed to take that topic up at the next meeting.
We would like to see the Board recognize ANRI / NORI as an entity that can grant Specialist Certificates.
Dr. Huber reminded the group that back around 2015, she and another physician addressed the Board at one of their meetings in the Public Section. The Board listened as they both described the history, the philosophy, mission and purpose of ANRI / NORI. As required by statute, the Board made no oral comments. However, by statute the Board was required to take minutes of that public announcement by two of our members. It is in statute that the Board must record the gist of all public comments.
UPCOMING HOUSE AND SENATE BILLS REGARDING INFORMED CONSENT
The proposed AZ House bill to restrict personal exemptions for vaccines has not been assigned to a Committee as of this past Monday. So that bill probably won’t go anywhere.
However, it also looks like the Senate Bill 1115 won’t go anywhere either. That also has not been assigned to a Committee.
OUR WEBSITE, NATUROPATHICSTANDARDS.ORG
Dr. Huber mentioned that the website is always subject to editing by members of the group. If the Informed Consent, as is, is useful to any of the doctors, it is at your disposal. Otherwise, please edit it to suit your purposes, if it can be of any use.
If anybody is working on any research articles, we would be honored to receive and read them.
One of the physicians presented a case of a St. 4 Inflammatory br ca patient, metastasized breast to bones. The physician did an IRB-approved therapy on this patient. He showed photos to the group. This patient had never had chemotherapy or radiation. Her pain level was reported as 14 (out of 1 to 10). That was 3 weeks ago. Then, after 3 weeks, she now reports “no pain” after only one treatment of this therapy. Breast tissue was soft and weepy at first, then scabbed over after treatment. Harold Dvorak wrote that “cancer is an unhealed wound.”  This left her with only a little pain in the upper inner quadrants of both breasts.
The physician was urged to get follow-up imaging, of the same type as previous imaging, in order to see what the effect has been on the patient’s tumor burden.
A SUPPLEMENT COMPANY
ProAlgaZyme does not seem to be available any longer, one of the non-physician members noted.
The next meeting has been placed on the schedule: Friday, May 10, 2019.
 Dvorak, Harold. Tumors: Wounds that do not heal – Redux. Cancer Immunol Res.. 2015 Jan 3 (1). 1-11. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4288010/